文献速递慢性肾脏病肾血管病与高血压

慢性肾脏病中的动脉粥样硬化性心血管疾病:发病机制、诊断与管理的当代见解

Atherosclerotic Cardiovascular Disease in CKD: Contemporary Insights into Pathogenesis, Diagnosis, and Management.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-09-14

本综述聚焦非透析依赖CKD患者,阐述动脉粥样硬化性心血管疾病(ASCVD)的流行病学与CKD相关非传统机制,评估CKD适配风险方程、心脏生物标志物及无创影像等诊断工具,并汇总降脂、抗血小板、降压、新型心肾代谢药物及血运重建等管理证据。

要点

  • CKD患者ASCVD负担随肾功能下降陡升,但常被低估和欠治疗。
  • CKD相关非传统机制包括血管钙化、炎症氧化应激、尿毒症毒素及致动脉粥样硬化性血脂异常。
  • 多数心血管 landmark 试验排除晚期CKD患者,CKD特异性高质量证据仍缺乏。

核心结论

  • 识别并积极干预CKD患者传统及CKD特异性心血管风险通路,是降低该高危人群发病率和死亡率的重大但尚未充分实现的机遇。

研究设计与样本

  • 本综述主要聚焦非透析依赖CKD患者的冠状动脉疾病,未报告系统检索范围。

主要发现

  • CKD患者心血管疾病负担不成比例,多数在进展至肾衰竭前死于心血管原因。
  • ASCVD包括冠状动脉疾病、脑血管疾病和外周动脉疾病,由传统危险因素与CKD相关非传统机制共同驱动。
  • 心血管与肾脏疾病呈双向交互,彼此加速进展。
  • 在最低eGFR和最高白蛋白尿水平时,心肌梗死、卒中和外周动脉疾病风险达数倍升高。
  • CKD中ASCVD因不典型临床表现、传统风险预测工具低估风险及 landmark 试验排除晚期CKD患者而认识不足和治疗不足。

关键数值与推荐

  • ASCVD负担随肾功能下降陡升,在最低eGFR和最高白蛋白尿时心肌梗死、卒中及外周动脉疾病风险达数倍升高。

临床怎么用

  • 应识别并积极干预CKD患者传统及CKD特异性心血管风险通路以降低发病率和死亡率。
  • 可应用CKD适配风险方程、心脏生物标志物及无创影像辅助诊断与风险预测。
  • 管理涵盖降脂、抗血小板、降压、SGLT2抑制剂、GLP-1受体激动剂、非甾体盐皮质激素受体拮抗剂、冠状动脉血运重建及生活方式调整。

局限性

  • 高质量CKD特异性证据缺乏,需优先填补研究空白。
  • 多数 landmark 心血管试验排除晚期CKD患者。
  • 传统风险预测工具在CKD中低估风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with CKD have a disproportionate burden of cardiovascular (CV) disease, and the majority die from CV causes before ever reaching kidney failure. Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease, cerebrovascular disease, and peripheral arterial disease, develops in CKD through the convergence of traditional risk factors and a distinct group of CKD-related, nontraditional mechanisms, including mineral and bone disorder with vascular calcification, chronic inflammation and oxidative stress, uremic toxicity, and an atherogenic dyslipidemia. CV and kidney disease interact in a bidirectional manner in which each accelerates the other. Reflecting this unique pathophysiology, the burden of ASCVD rises steeply as kidney function declines, reaching a several-fold higher risk of myocardial infarction, stroke, and peripheral arterial disease at the lowest eGFR and highest albuminuria. Nonetheless, ASCVD in CKD remains under-recognized and undertreated, owing partly to atypical clinical presentations, conventional risk-prediction tools that underestimate risk, and to the exclusion of patients with advanced CKD from most landmark CV trials. In this review, which focuses primarily on coronary artery disease in non-dialysis-dependent CKD, we examine the epidemiology and key pathogenic mechanisms of ASCVD in this setting and appraise diagnostic and risk-prediction approaches together with their limitations, including contemporary CKD-adapted risk equations, cardiac biomarkers, and noninvasive imaging. We also summarize the current evidence for management, spanning lipid-lowering, antiplatelet, and BP therapies, newer cardiometabolic agents (including sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists), coronary revascularization, and lifestyle modification. Throughout, we highlight where high-quality, CKD-specific evidence is lacking, and we outline priority research gaps and emerging therapies directed at CKD-relevant pathways, such as inflammation. Recognizing and aggressively modifying CV risk in CKD, across both traditional and CKD-specific pathways, represents a substantial, and currently underrealized, opportunity to reduce morbidity and mortality in this high-risk population.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Correa S, Cunningham JW, Mc Causland FR, et al. Atherosclerotic Cardiovascular Disease in CKD: Contemporary Insights into Pathogenesis, Diagnosis, and Management. Clin J Am Soc Nephrol. 2026. PMID: 42735033. doi:10.2215/CJN.0000001199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。